Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own22.62% Shs Outstand35.38M Perf Week-3.09%
Market Cap897.94M Forward P/E- EPS next Y- Insider Trans7.51% Shs Float27.37M Perf Month-
Income- PEG- EPS next Q- Inst Own0.20% Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh-1.12 P/B- EPS next Y- ROA- Short Interest- Perf Year-
Cash/sh5.46 P/C4.64 EPS next 5Y- ROE- 52W Range18.00 - 27.11 Perf YTD22.02%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-6.38% Beta-
Dividend TTM- Quick Ratio20.10 Sales past 5Y0.00% Gross Margin- 52W Low41.00% ATR (14)4.61
Dividend Ex-Date- Current Ratio20.10 EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility21.32% -
Employees52 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q- Payout- Rel Volume0.35 Prev Close24.30
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume554.67K Price25.38
SMA2010.41% SMA5010.41% SMA20010.41% Trades Volume194,085 Change4.44%
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HEALY JAMESDirectorJun 10 '24Buy17.00558,8249,500,0081,863,327Jun 10 07:38 PM